HARP Harpoon Therapeutics Inc.

21.76
+1.17  (+6%)
Previous Close 20.59
Open 19.6
Price To Book 6.54
Market Cap 543,954,652
Shares 24,997,916
Volume 625,253
Short Ratio
Av. Daily Volume 147,911
Stock charts supplied by TradingView

NewsSee all news

  1. Harpoon Therapeutics Presents Interim Phase 1 Data from an Ongoing Dose Escalation Trial for the PSMA-targeting TriTAC® HPN424 at the ASCO20 Virtual Scientific Program

    The on-going dose escalation Phase 1 study has enrolled 44 patients with progressive, metastatic castration-resistant prostate cancer in 11 cohorts. Initial safety data showed that HPN424 is generally well-tolerated, and

  2. Harpoon Therapeutics to Present Interim Clinical Data for TriTAC® HPN424 at the ASCO20 Virtual Scientific Program

    SOUTH SAN FRANCISCO, Calif., May 22, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced today that interim

  3. Harpoon Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

    Dosed first patient with HPN217 for the treatment of multiple myeloma, triggering a $50 million milestone payment from AbbVieAbstract for HPN424 interim Phase 1 data accepted for presentation at ASCO20 Virtual SOUTH SAN

  4. Harpoon Therapeutics Doses First Patient with HPN217, a BCMA Targeting TriTAC, for Multiple Myeloma

    SOUTH SAN FRANCISCO, Calif., April 27, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that the

  5. Harpoon Therapeutics Reports Fourth Quarter 2019 Financial Results and Provides Corporate Update

    Exclusive worldwide option and license transaction for HPN217 with AbbVie and expansion of existing discovery collaboration in November 2019 could provide up to $100 million in upfront/near-term milestones and up to $2.3

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2a data due 2H 2020.
HPN536
Ovarian cancer
Phase 1 preliminary data at ASCO May 29, 2020 - generally well-tolerated.
HPN424
Metastatic castration-resistant prostate cancer
Phase 1/2 initiation of dosing announced April 27, 2020.
HPN217
Multiple myeloma
Phase 1/2a trial to be initiated 2H 2020.
HPN328
Small cell lung cancer

Latest News

  1. Harpoon Therapeutics Presents Interim Phase 1 Data from an Ongoing Dose Escalation Trial for the PSMA-targeting TriTAC® HPN424 at the ASCO20 Virtual Scientific Program

    The on-going dose escalation Phase 1 study has enrolled 44 patients with progressive, metastatic castration-resistant prostate cancer in 11 cohorts. Initial safety data showed that HPN424 is generally well-tolerated, and

  2. Harpoon Therapeutics to Present Interim Clinical Data for TriTAC® HPN424 at the ASCO20 Virtual Scientific Program

    SOUTH SAN FRANCISCO, Calif., May 22, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced today that interim

  3. Harpoon Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

    Dosed first patient with HPN217 for the treatment of multiple myeloma, triggering a $50 million milestone payment from AbbVieAbstract for HPN424 interim Phase 1 data accepted for presentation at ASCO20 Virtual SOUTH SAN

  4. Harpoon Therapeutics Doses First Patient with HPN217, a BCMA Targeting TriTAC, for Multiple Myeloma

    SOUTH SAN FRANCISCO, Calif., April 27, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that the

  5. Harpoon Therapeutics Reports Fourth Quarter 2019 Financial Results and Provides Corporate Update

    Exclusive worldwide option and license transaction for HPN217 with AbbVie and expansion of existing discovery collaboration in November 2019 could provide up to $100 million in upfront/near-term milestones and up to $2.3

  6. Harpoon Therapeutics to Report Fourth Quarter 2019 Financial Results and Provide Corporate Update

    SOUTH SAN FRANCISCO, Calif., March 05, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced today that it will

  7. Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald

  8. Harpoon Therapeutics to Participate in the Piper Jaffray Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald

  9. Harpoon Therapeutics and AbbVie Announce Licensing and Option Collaboration to Advance HPN217, Harpoon's BCMA-Targeting TriTAC®, and Expand Existing Discovery Collaboration

    Harpoon grants AbbVie option to license worldwide rights to HPN217 (BCMA), a TriTAC for the treatment of multiple myeloma planned for IND filing this year Expanded TriTAC discovery collaboration includes up to six

  10. Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald

  11. Harpoon Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    Continued enrollment and dose escalation of Phase 1 trial for HPN424 and Phase 1/2a trial for HPN536, Harpoon's lead TriTAC® product candidates in development for the treatment of prostate and ovarian and pancreatic

  12. Harpoon Therapeutics Presents Preclinical Data for HPN328, a DLL3-targeting T Cell Engager, at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

    HPN328, a TriTAC®, Exhibits the Potency, Tolerability, and Pharmacokinetics to Support Initiation of Clinical Development in 2020 SOUTH SAN FRANCISCO, Calif., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics,